RENEW

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)

Arms / Cohorts

Experimental:KER-050

Status
Status not available
Overview
Overview not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Placebo Comparator:Placebo Comparator

Status
Status not available
Overview
Overview not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

(888) 803-1766

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.